Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: A pilot study

被引：89

作者：

Sin D.D. ^{[1
,2
]}

Leung R. ^{[1
,2
]}

Gan W.Q. ^{[1
,2
]}

Man S.F.P. ^{[1
,2
]}

机构：

[1] The University of British Columbia, Respiratory Division, Vancouver, BC

[2] The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St. Paul's Hospital, Vancouver, BC V6Z 1Y6

来源：

BMC Pulmonary Medicine | / 7卷 / 1期

关键词：

Chronic Obstructive Pulmonary Disease; Chronic Obstructive Pulmonary Disease Patient; Severe Chronic Obstructive Pulmonary Disease; Chronic Respiratory Disease Questionnaire; Advanced Chronic Obstructive Pulmonary Disease;

D O I：

10.1186/1471-2466-7-13

中图分类号：

学科分类号：

摘要：

Background: There is a paucity of surrogate lung-specific biological markers that can be used to track disease progression and predict clinical outcomes in chronic obstructive pulmonary disease (COPD). The principal aim of this pilot study was to determine whether circulating surfactant protein D (SPD) or Clara Cell protein-16 (CC16) levels are associated with lung function or health status in patients with severe COPD. Methods: We studied 23 patients with advanced COPD. Lung function measurements, Chronic Respiratory Disease Questionnaire (CRQ) scores, and serum levels of SPD, CC16, and C-reactive protein (CRP) were determined at baseline and at 3 months. Results: At baseline, FEV1 was inversely associated with serum SPD levels (P = 0.045) but not with CC16 (P = 0.675) or CRP levels (P = 0.549). Over a 3 month period, changes in SPD levels correlated significantly with changes in CRQ scores (adjusted P = 0.008) such that patients who had the largest declines in serum SPD levels experienced the largest gains in health status. The association was particularly notable between circulating SPD level and the dyspnea domain of the CRQ score (P = 0.018). Changes in CC16 or CRP levels did not correlate with changes in CRQ scores. Conclusion: Changes in serum SPD levels tracked well with changes in health status over a 3 month period in patients with severe COPD. These data suggest that circulating SPD levels may be useful biomarkers to track health outcomes of COPD patients. © 2007 Sin et al.; licensee BioMed Central Ltd.

引用

共 22 条

[1] Murray C.J., Lopez A.D., Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study, Lancet, 349, 9063, pp. 1436-1442, (1997)
[2] Barnes P.J., Stockley R.A., COPD: Current therapeutic interventions and future approaches, Eur Respir J, 25, 6, pp. 1084-1106, (2005)
[3] Franciosi L.G., Page C.P., Celli B.R., Cazzola M., Walker M.J., Danhof M., Rabe K.F., Della Pasqua O.E., Markers of exacerbation severity in chronic obstructive pulmonary disease, Respir Res, 7, (2006)
[4] Man S.F., Connett J.E., Anthonisen N.R., Wise R.A., Tashkin D.P., Sin D.D., C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease, Thorax, 61, 10, pp. 849-853, (2006)
[5] Pepys M.B., Hirschfield G.M., C-reactive protein: A critical update, J Clin Invest, 111, 12, pp. 1805-1812, (2003)
[6] Hermans C., Dong P., Robin M., Jadoul M., Bernard A., Bersten A.D., Doyle I.R., Determinants of serum levels of surfactant proteins A and B and Clara cell protein CC16, Biomarkers, 8, 6, pp. 461-471, (2003)
[7] Sin D.D., Wong E., Mayers I., Lien D.C., Feeny D., Cheung H., Gan W.Q., Man S.F., Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD, Chest, 131, 1, pp. 156-163, (2007)
[8] Society A.T., Chronic Respiratory Disease Questionnaire-CRQ
[9] Kushner I., Rzewnicki D., Samols D., What does minor elevation of C-reactive protein signify?, Am J Med, 119, 2, (2006)
[10] Atochina E.N., Beers M.F., Hawgood S., Poulain F., Davis C., Fusaro T., Gow A.J., Surfactant protein-D, a mediator of innate lung immunity, alters the products of nitric oxide metabolism, Am J Respir Cell Mol Biol, 30, 3, pp. 271-279, (2004)

← 1 2 3 →